bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
0.2635
-0.0237 (-8.25%)
At close: Jul 1, 2025, 4:00 PM
0.2585
-0.0050 (-1.90%)
After-hours: Jul 1, 2025, 7:57 PM EDT
bioAffinity Technologies Employees
bioAffinity Technologies had 57 employees as of December 31, 2024. The number of employees decreased by 18 or -24.00% compared to the previous year.
Employees
57
Change (1Y)
-18
Growth (1Y)
-24.00%
Revenue / Employee
$154,548
Profits / Employee
-$170,850
Market Cap
7.25M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57 | -18 | -24.00% |
| Dec 31, 2023 | 75 | 61 | 435.71% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
BIAF News
- 5 days ago - bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference - Business Wire
- 7 days ago - bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy - Business Wire
- 20 days ago - bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board - Business Wire
- 4 weeks ago - bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics - Business Wire
- 6 weeks ago - bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer - Business Wire
- 6 weeks ago - bioAffinity Technologies Reports First Quarter 2025 Results - Business Wire
- 7 weeks ago - Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer - Business Wire
- 7 weeks ago - WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering - PRNewsWire